Singapore: Hummingbird Bioscience closes US$125m Series C financing round

Hummingbird Bioscience, a clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has closed a US$125m Series C financing round. The financing was led by Novo Holdings. Proceeds will be used to advance the clinical development of Hummingbird’s lead assets, expand the capabilities of Hummingbird’s proprietary Rational Antibody Discovery platform and progress the…

You must be a HMI Subscriber to view this content.

Subscribe Now »